Leukemia
Midostaurin for Patients With Acute Myeloid Leukemia and FLT3 Mutations
Mark James Levis, MD, PhD
H&O What is the role of FLT3 in normal cells and acute myeloid leukemia? ML FLT3 is a receptor tyrosine kinase. The name stands for […]
In This Issue
Breast Cancer
The Dawn of Immunotherapy for Breast Cancer
Leisha A. Emens, MD, PhD
Hematology
Diagnosis and Treatment of Hemophilia
Hande Kizilocak, MD, and Guy Young, MD
Lymphoma
Surveillance Scanning in Lymphoma
Sarah C. Rutherford, MD
From Recent Issues
Colorectal Cancer
Immunotherapy in Colorectal Cancer With Mismatch Repair Deficiency
H&O Which immunotherapy agents have been approved for use in colorectal cancer (CRC) with mismatch repair deficiency (MMR-D)? MO We have a choice of 3 […]
Myelofibrosis
The Evolving Understanding of Prognosis in Post–Essential Thrombocythemia Myelofibrosis and Post–Polycythemia Vera Myelofibrosis vs Primary Myelofibrosis
Abstract: Myelofibrosis (MF) is the most aggressive of the classic Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs). In some patients with essential thrombocytopenia or polycythemia vera, which […]
Leukemia
Does FCR Have the Potential to Cure a Subgroup of Patients With Chronic Lymphocytic Leukemia?
H&O When is first-line treatment initiated in patients with CLL? WW In chronic lymphocytic leukemia (CLL), patients should meet a standard criteria to initiate treatment. […]
Supplements
lymphoma
Highlights in CAR T-Cell Therapy in Lymphoma From the 60th American Society of Hematology Annual Meeting
A Review of Selected Presentations From the 60th American Society of Hematology Annual Meeting • December 1-4, 2018 • San Diego, California 2-Year Follow-Up and High-Risk […]
Multiple Myeloma
A Clinician’s Perspective of Treatment of Relapsed or Refractory Multiple Myeloma
Click the “Download PDF” button to read Dr. Paul G. Richardson’s perspective on treatment of relapsed or refractory multiple myeloma.
Prostate Cancer
Highlights in Advanced Prostate Cancer From the 2019 ASCO Genitourinary Cancers Symposium
A Review of Selected Presentations From the 2019 ASCO Genitourinary Cancers Symposium • February 14-16, 2019 • San Francisco, California ARAMIS: Efficacy and Safety of […]
Melanoma
The Future of Combination Treatment With Checkpoint Inhibitors in Melanoma
H&O What dual checkpoint blockade regimens have been approved for use in metastatic melanoma? RS So far, the only approved option is the combination of […]
The Current Role of Intralesional Therapy in Advanced Melanoma
H&O Which patients with melanoma are potential candidates for intralesional therapy? RA To undergo intralesional therapy, patients must have injectable lesions, which may be dermal, […]
Immunotherapy in the Adjuvant Setting for High-Risk Melanoma
H&O Which patients with melanoma are at elevated risk for a recurrence after surgical resection? JW A patient at elevated risk is one whose 5-year […]